SCHEMBL20575083

SCHEMBL20575083

O=C(O)CC(c1ccccc1)[S+]([O-])c1ccc(NC(=O)c2ccc(NC3=CCCCN3)cc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
POLB P06746 3/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
ITGB3 P05106 3/20 0.34
ITGA2B P08514 2/20 0.34
ITGA2 P17301 2/20 0.34
PTPN1 P18031 1/20 0.34
HPGD P15428 1/20 0.34
GSK3B P49841 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
BLM P54132 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20574531 0.92 ITGB3 (0.42) NPC1RAB9AITGB3ITGA2BSMN1; SMN2
SCHEMBL20575049 0.91 ITGB3 (0.38) MEN1KMT2APOLBITGB3ITGA2B
SCHEMBL20575157 0.91 ITGB3 (0.41) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL20575222 0.87 HDAC1 (0.33) MEN1KMT2APOLBNR1H4ITGB3
SCHEMBL20575628 0.84 ITGB3 (0.42) ITGB3ITGA2BITGAV
SCHEMBL20575094 0.84 ITGB3 (0.42) NPC1RAB9AITGB3ITGA2BSMN1; SMN2
SCHEMBL20575184 0.84 ITGB3 (0.39) KMT2APOLBITGB3ITGA2BITGA2
SCHEMBL2837003 0.84 ITGB3 (0.48) ITGB3ITGA2BITGAV
SCHEMBL20574516 0.81 KMT2A (0.41) MEN1KMT2APOLBKDM4EHPGD
SCHEMBL4236953 0.81 ADRA2A (0.47) ITGB3ITGA2BITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180344803-A1 Methods and Compositions For the Treatment of Proteinuric Diseases THE GENERAL HOSPITAL CORPORATION 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180344803-A1 Methods and Compositions For the Treatment of Proteinuric Diseases ITGB3, PLAUR, PROC MEN1 3989/4885KMT2A 4406/4885POLB 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.